Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.86 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.86 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.84 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.84 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.84 |
| ▸ | FLT3 | P36888 | 2/20 | 0.82 |
| ▸ | AURKA | O14965 | 1/20 | 0.82 |
| ▸ | KDR | P35968 | 1/20 | 0.82 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 5/20 | 0.78 |
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 3/20 | 0.77 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cirsileneol SCHEMBL29435128 | 1.00 | HSD17B2 (0.86) | HSD17B2TAS2R31CYP1A1CYP1B1CYP1A2 | |
| Jaceosidine SCHEMBL3960077 | 0.93 | HSD17B2 (1.00) | HSD17B2TAS2R31CYP1A1CYP1B1CYP1A2 | |
| Jaceosidine SCHEMBL29926544 | 0.93 | HSD17B2 (1.00) | HSD17B2TAS2R31CYP1A1CYP1B1CYP1A2 | |
| Cirsiliol SCHEMBL29928874 | 0.93 | CYP1A1 (0.86) | HSD17B2TAS2R31CYP1A1CYP1B1CYP1A2 | |
| Cirsiliol SCHEMBL1614677 | 0.93 | CYP1A1 (0.86) | HSD17B2TAS2R31CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL10031342 | 0.93 | CYP1A1 (0.81) | HSD17B2TAS2R31CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL34468184 | 0.91 | CYP1B1 (1.00) | HSD17B2TAS2R31CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL31238120 | 0.91 | CYP1B1 (1.00) | HSD17B2TAS2R31CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3131502 | 0.91 | CYP1B1 (1.00) | HSD17B2TAS2R31CYP1A1CYP1B1CYP1A2 | |
| Eupatorin SCHEMBL29386042 | 0.90 | CYP1A1 (1.00) | HSD17B2TAS2R31CYP1A1CYP1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| WO-2024220449-A9 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2025-04-03 | — | — | WO | claimed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | claimed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| EP-4203943-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | ArtemiFlow GmbH (DE) | 2023-07-05 | — | — | EP | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021191169-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE TREATMENT OF COVID-19 | Artemiflow GmbH (DE) | 2021-09-30 | — | — | WO | claimed |
| EP-3884938-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE TREATMENT OF COVID-19 | ArtemiFlow GmbH (DE) | 2021-09-29 | — | — | EP | claimed |
| US-20210292296-A1 | 1,2,4-Trioxane compounds and compositions comprising the same for use in the treatment of COVID-19 | Artemiflow GmbH (DE) | 2021-09-23 | — | — | US | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| EP-1771200-B1 | PHYSIOLOGICALLY-ACTIVE COMPOSITION BASED ON COLLAGEN | CARGILL INC (US) | 2011-06-08 | — | — | EP | claimed |
| US-20090005322-A1 | Physiologically- Active Composition Based on Collagen | CARGILL, INCORPORATED | 2009-01-01 | — | — | US | claimed |
| CN-101022823-A | Physiologically active composition based on collagen | CARGILL INC (US) | 2007-08-22 | — | — | CN | claimed |
| EP-1771200-A1 | PHYSIOLOGICALLY-ACTIVE COMPOSITION BASED ON COLLAGEN | Gargill Incorporated (US) | 2007-04-11 | — | — | EP | claimed |
| WO-2006010606-A1 | PHYSIOLOGICALLY-ACTIVE COMPOSITION BASED ON COLLAGEN | CARGILL, INCORPORATED (US) | 2006-02-02 | — | — | WO | claimed |
| US-20260115294-A1 | DERIVATIVES OF 5-HYDROXYLATED POLYMETHOXYFLAVONES WITH ENHANCED BIOAVAILABILITY FOR ORAL DELIVERY AND COMPOSITIONS THEREOF | DEEPSENSE BIOTECHNOLOGIES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12569530-B2 | Tannin-based antiproliferative pharmaceutical | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2026-03-10 | — | — | US | disclosed |
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12453799-B1 | Bioadhesive for medical and dental applications | IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) | 2025-10-28 | — | — | US | disclosed |
| US-20250249063-A1 | METHOD FOR TREATING ORAL CANCER | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-08-07 | — | — | US | disclosed |
| US-20250197898-A1 | ISOTHIOCYANATE CONTAINING BRASSICACEAE PRODUCTS AND METHOD OF PREPARATION THEREOF | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2025-06-19 | — | — | US | disclosed |
| US-12318422-B2 | Tannin-based antiproliferative pharmaceutical | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2025-06-03 | — | — | US | disclosed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2024220449-A9 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025068966-A2 | SYNERGISTIC DENTIFRICE (ORAL) COMPOSITION, FORMULATION AND PREPARATION METHOD AND APPLICATION THEREOF | RAI BALWANT (IN) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025049925-A2 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | POSEIDA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-12227780-B2 | Isothiocyanate containing Brassicaceae products and method of preparation thereof | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2025-02-18 | — | — | US | disclosed |
| US-20250046528-A1 | ELECTROLYTIC CAPACITOR AND LIQUID COMPONENT FOR ELECTROLYTIC CAPACITOR | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240355451-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | NESTLE SA (CH) | 2024-10-24 | — | — | US | disclosed |
| US-20240350476-A1 | Smoking Cessation Aid | Lucy Goods, Inc. | 2024-10-24 | — | — | US | disclosed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240293492-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2024-09-05 | — | — | US | disclosed |
| EP-4401711-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401712-A1 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401714-A1 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401713-A1 | ALIMENTARY-RELATED PARTICLES, PRODUCTION METHODS, AND PRODUCTION APPARATUS | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240216296-A1 | POLYPHENOL COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY | EPICEUTICAL LABS LLC | 2024-07-04 | — | — | US | disclosed |
| EP-4391834-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | Société des Produits Nestlé S.A. (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-12018086-B2 | Kit comprising contiguous nucleobases, including position 76, of RS5745994 | CEDARS-SINAI MEDICAL CENTER (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024107938-A2 | POLYPHENOL LIPID NANOPARTICLES AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240165036-A1 | ENCAPSULATED VITAMIN D | Nulixir Inc. | 2024-05-23 | — | — | US | disclosed |
| CN-117837498-A | Method for improving and regulating synthesis of flavonoids in saussurea involucrata leaves | 石河子大学 | 2024-04-09 | — | — | CN | disclosed |
| US-20240101791-A1 | POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024059282-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230404126-A1 | ENCAPSULATED PRECURSORS OF NICOTINAMIDE ADENINE DINUCLEOTIDE AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-12-21 | — | — | US | disclosed |
| US-20230321197-A1 | Polyphenolic Insulin | KIMBALL WESTWARD LLC (US) | 2023-10-12 | — | — | US | disclosed |
| CN-113717046-B | Bisphenol compound in herba Artemisiae Scopariae, and its preparation method and application | 深圳市人民医院 | 2023-09-26 | — | — | CN | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230241023-A1 | STABILIZATION OF 1,2,4-TRIOXANE COMPOUNDS BY CHLOROGENIC ACIDS | Artemiflow GmbH (DE) | 2023-08-03 | — | — | US | disclosed |
| WO-2023143608-A1 | COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | 上海复东生物医药有限责任公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230241023-A1 | STABILIZATION OF 1,2,4-TRIOXANE COMPOUNDS BY CHLOROGENIC ACIDS | Artemiflow GmbH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230241023-A1 | STABILIZATION OF 1,2,4-TRIOXANE COMPOUNDS BY CHLOROGENIC ACIDS | Artemiflow GmbH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230210931-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-06 | — | — | US | disclosed |
| EP-4203943-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | ArtemiFlow GmbH (DE) | 2023-07-05 | — | — | EP | disclosed |
| EP-4192507-A1 | POLYPHENOLIC INSULIN | Kimball Westward LLC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230157973-A1 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-05-25 | — | — | US | disclosed |
| US-20230157963-A1 | SOLID ORAL BEADS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-05-25 | — | — | US | disclosed |
| US-20230149346-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | Artemiflow GmbH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230149346-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | Artemiflow GmbH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230149346-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | Artemiflow GmbH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230149829-A1 | ORAL COMPOSITIONS OF PLANTS THROUGH A DOUBLE EXTRACTION SYSTEM AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230111756-A1 | STABLE FORMULATIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-04-13 | — | — | US | disclosed |
| US-20230111190-A1 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-04-13 | — | — | US | disclosed |
| US-20230110485-A1 | MULTI-LAYER PARTICLES OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-04-13 | — | — | US | disclosed |
| US-20230111238-A1 | STABLE COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-04-13 | — | — | US | disclosed |
| EP-4157253-A1 | STABILIZATION OF 1,2,4-TRIOXANE COMPOUNDS BY CHLOROGENIC ACIDS | ArtemiFlow GmbH (DE) | 2023-04-05 | — | — | EP | disclosed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | disclosed |
| WO-2023043855-A1 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043852-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043853-A1 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043854-A1 | ALIMENTARY-RELATED PARTICLES, PRODUCTION METHODS, AND PRODUCTION APPARATUS | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20230079480-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
| US-20230081296-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
| US-20230082651-A1 | STABLE AQUEOUS COMPOSITIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
| WO-2023025722-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | Société des Produits Nestlé S.A. (CH) | 2023-03-02 | — | — | WO | disclosed |
| US-11547122-B2 | Preventing physical instability of heat treated dairy based products | ARLA FOODS AMBA (DK) | 2023-01-10 | — | — | US | disclosed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| US-11376570-B1 | Method of forming copper oxide-on-copper nanomaterial catalyst mesh | KING ABDULAZIZ UNIVERSITY (SA) | 2022-07-05 | — | — | US | disclosed |
| US-20220160802-A1 | METHODS AND COMPOSITIONS FOR PROMOTING HEALTH IN A SUBJECT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2022-05-26 | — | — | US | disclosed |
| US-20220153855-A1 | METHODS OF PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE | CEDARS-SINAI MEDICAL CENTER | 2022-05-19 | — | — | US | disclosed |
| US-11311492-B1 | Carbon nanomedicine with natural ligands | KING ABDULAZIZ UNIVERSITY (SA) | 2022-04-26 | — | — | US | disclosed |
| US-11234940-B1 | Method for making a noble metal nanomedicine | KING ABDULAZIZ UNIVERSITY (SA) | 2022-02-01 | — | — | US | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11219605-B1 | Metal nanoparticle medicine with a mixture of natural ligands | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-11 | — | — | US | disclosed |
| US-11206835-B2 | Air purification composition with antiviral and bactericidal functions | Guorun Biotechnology (Shenzhen) Co., Ltd. (CN) | 2021-12-28 | — | — | US | disclosed |
| US-11180565-B2 | Method of enriching a target nucleic acid at a TNFRSF1B gene locus in a sample from a subject with inflammatory bowel disease | CEDARS-SINAI MEDICAL CENTER (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2021191169-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE TREATMENT OF COVID-19 | Artemiflow GmbH (DE) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191169-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE TREATMENT OF COVID-19 | Artemiflow GmbH (DE) | 2021-09-30 | — | — | WO | disclosed |
| EP-3884938-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE TREATMENT OF COVID-19 | ArtemiFlow GmbH (DE) | 2021-09-29 | — | — | EP | disclosed |
| US-11129797-B1 | Catechin and gingerol loaded nanomedicine | KING ABDULAZIZ UNIVERSITY (SA) | 2021-09-28 | — | — | US | disclosed |
| US-20210292296-A1 | 1,2,4-Trioxane compounds and compositions comprising the same for use in the treatment of COVID-19 | Artemiflow GmbH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210292296-A1 | 1,2,4-Trioxane compounds and compositions comprising the same for use in the treatment of COVID-19 | Artemiflow GmbH (DE) | 2021-09-23 | — | — | US | disclosed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3862002-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3672428-B1 | PREVENTING PHYSICAL INSTABILITY OF HEAT TREATED DAIRY BASED PRODUCTS | ARLA FOODS AMBA (DK) | 2021-07-07 | — | — | EP | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210113596-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10881676-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3354282-B1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200352185-A1 | PREVENTING PHYSICAL INSTABILITY OF HEAT TREATED DAIRY BASED PRODUCTS | ARLA FOODS AMBA (DK) | 2020-11-12 | — | — | US | disclosed |
| US-20200329717-A1 | NOVEL AIR PURIFICATION COMPOSITION WITH ANTIVIRAL AND BACTERICIDAL FUNCTIONS | Guorun Biotechnology (Shenzhen) Co., Ltd. (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200255872-A1 | Isothiocyanate containing Brassicaceae Products and Method of Preparation Thereof | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2020-08-13 | — | — | US | disclosed |
| EP-3688179-A1 | ISOTHIOCYANATE CONTAINING BRASSICACEAE | Commonwealth Scientific and Industrial Research Organisation (AU) | 2020-08-05 | — | — | EP | disclosed |
| US-20200231690-A1 | METHODS OF PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE | CEDARS-SINAI MEDICAL CENTER | 2020-07-23 | — | — | US | disclosed |
| US-10702542-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-3672428-A1 | PREVENTING PHYSICAL INSTABILITY OF HEAT TREATED DAIRY BASED PRODUCTS | Arla Foods Amba (DK) | 2020-07-01 | — | — | EP | disclosed |
| EP-3650105-A1 | NOVEL AIR PURIFICATION COMPOSITION HAVING ANTIVIRAL AND BACTERICIDAL FUNCTIONS | Wang, Jingning (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-10626180-B2 | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease | CEDARS-SINAI MEDICAL CENTER (US) | 2020-04-21 | — | — | US | disclosed |
| US-20200093851-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200093845-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10314853-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| WO-2019060963-A1 | ISOTHIOCYANATE CONTAINING BRASSICACEAE PRODUCTS AND METHOD OF PREPARATION THEREOF | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019038392-A1 | PREVENTING PHYSICAL INSTABILITY OF HEAT TREATED DAIRY BASED PRODUCTS | ARLA FOODS AMBA (DK) | 2019-02-28 | — | — | WO | disclosed |
| CN-108770890-A | A kind of air purifying composition of novel antiviral sterilizing function | 王婧宁 | 2018-11-09 | — | — | CN | disclosed |
| US-20180305459-A1 | METHODS OF PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE | CEDARS-SINAI MEDICAL CENTER | 2018-10-25 | — | — | US | disclosed |
| WO-2018195328-A1 | METHODS OF PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE | CEDARS-SINAI MEDICAL CENTER (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180235987-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3354282-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3334437-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | Kaleido Biosciences, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180147222-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2018-05-31 | — | — | US | disclosed |
| US-9901595-B2 | Glycan therapeutics for reducing blood ammonia | KALEIDO BIOSCIENCES, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| CN-107624826-A | A kind of air bacteriostatic agent and preparation method thereof | 纪宏 | 2018-01-26 | — | — | CN | disclosed |
| US-9757403-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170246201-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170151268-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151269-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| CN-106562071-A | Plant dog food composition and preparation method thereof | 上海翼邦生物技术有限公司 | 2017-04-19 | — | — | CN | disclosed |
| WO-2017035412-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| CN-106138082-A | A kind of RNA nucleic acid strengthening radiotherapy in lung cancer sensitiveness and application | 滨州医学院 | 2016-11-23 | — | — | CN | disclosed |
| US-9492473-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3071235-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9415034-B2 | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2016-08-16 | — | — | US | disclosed |
| WO-2016122889-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160184298-A1 | INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) | NAT DEFENSE MEDICAL CT (TW) | 2016-06-30 | — | — | US | disclosed |
| US-20150150770-A1 | METHODS OF TREATING SKIN | TRACIE MARTYN INTERNATIONAL INC (US) | 2015-06-04 | — | — | US | disclosed |
| CN-103848843-A | Method for extracting active ingredient of folium artemisiae argyi and application of active ingredient in resistance of plant disease | UNIV GUIZHOU | 2014-06-11 | — | — | CN | disclosed |
| US-20140155961-A1 | METHODS OF TREATING SKIN | Tracie Martyn International, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8653095-B2 | Small molecules with antimalarial activity | RADIX PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| CN-103232425-A | Method for extracting scoparone from artemisia capillaris | NANJING ZELANG AGRI DEV CO LTD | 2013-08-07 | — | — | CN | disclosed |
| US-20130137759-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASE | WORCESTER POLYTECHNIC INSTITUTE (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130023552-A1 | Small molecules with antimalarial activity | RADIX PHARMACEUTICALS, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-02 | — | — | US | disclosed |
| WO-2011109745-A2 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASE | WORCESTER POLYTECHNIC INSTITUTE (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-1771200-B1 | PHYSIOLOGICALLY-ACTIVE COMPOSITION BASED ON COLLAGEN | CARGILL INC (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7851508-B2 | Natural product derivatives with antimalarial activity | RADIX PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20100272790-A1 | Methods of Treating Skin | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7776915-B2 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100087469-A1 | Natural product derivatives with antimalarial activity | RADIX PHARMACEUTICALS, INC. | 2010-04-08 | — | — | US | disclosed |
| US-7678768-B2 | Physiologically-active composition based on collagen | CARGILL INCORPORATED (US) | 2010-03-16 | — | — | US | disclosed |
| CN-100571696-C | Inhibitors and promoters of uridine diphosphate glucuronyl transferase 2B (UGT2B) | NAT DEFENSE EDUCATION RES FOUN (CN) | 2009-12-23 | — | — | CN | disclosed |
| CN-101448395-A | Compositions and methods for increasing the value of plant products, enhancing their commercial quality, enhancing their resistance to external agents and increasing their polyphenol content | ANTONI LESCHOT SANHUEZA ANDRES (CL) | 2009-06-03 | — | — | CN | disclosed |
| US-20090074708-A1 | Inhibitors and Enhancers of Uridine Diphosphate-Glucuronosyltransferase 2B (UGT2B) | NATIONAL DEFENSE MEDICAL UNIVERSITY (TW) | 2009-03-19 | — | — | US | disclosed |
| US-20090005322-A1 | Physiologically- Active Composition Based on Collagen | CARGILL, INCORPORATED | 2009-01-01 | — | — | US | disclosed |
| EP-2003968-A2 | COMPOSITIONS AND METHODS TO ADD VALUE TO PLANT PRODUCTS, SO INCREASING THE COMMERCIAL QUALITY, RESISTANCE TO EXTERNAL FACTORS AND POLYPHENOL CONTENT THEREOF | Leschot Sanhueza, Andres Antonio (CL) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008100977-A2 | CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS | N.V. ORGANON (NL) | 2008-08-21 | — | — | WO | disclosed |
| US-20070232495-A1 | Compositions and methods to add value to plant products, increasing the commercial quality, resistance to external factors and polyphenol content thereof | NAPPA ALVARO O | 2007-10-04 | — | — | US | disclosed |
| WO-2007110801-A2 | COMPOSITIONS AND METHODS TO ADD VALUE TO PLANT PORDUCTS, INCREASING THE COMMERCIAL QUALITY, RESISTANCE TO EXTERNAL FACTORS AND POLYPHENOL CONTENT THEREOF | LESCHOT SANHUEZA ANDRES ANTONI (CL) | 2007-10-04 | — | — | WO | disclosed |
| CN-101022823-A | Physiologically active composition based on collagen | CARGILL INC (US) | 2007-08-22 | — | — | CN | disclosed |
| EP-1771200-A1 | PHYSIOLOGICALLY-ACTIVE COMPOSITION BASED ON COLLAGEN | Gargill Incorporated (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060216251-A1 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2006-09-28 | — | — | US | disclosed |
| CN-1820743-A | Inhibitor or promoter of uridinediphosphate glucuronosyltransferase 2B (UGT2B) | HU OLIVER YOA PU (CN) | 2006-08-23 | — | — | CN | disclosed |
| US-20060040875-A1 | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) | NATIONAL DEFENSE MEDICAL CENTER | 2006-02-23 | — | — | US | disclosed |
| US-6998141-B2 | Medication combination for hepatoma and pancreatic cancer and preparation protocol | LEE CHIEN-YUNG | 2006-02-14 | — | — | US | disclosed |
| WO-2006010606-A1 | PHYSIOLOGICALLY-ACTIVE COMPOSITION BASED ON COLLAGEN | CARGILL, INCORPORATED (US) | 2006-02-02 | — | — | WO | disclosed |
| CN-1232270-C | A Chinese medicinal composition for treating hepatocarcinoma and pancreatic cancer, and its preparation method | LI JIANYONG (CN) | 2005-12-21 | — | — | CN | disclosed |
| CN-1491671-A | A Chinese medicinal composition for treating hepatocarcinoma and pancreatic cancer, and its preparation method | 李健勇 | 2004-04-28 | — | — | CN | disclosed |
| US-20030166583-A1 | Such as epicatechin coadministered with retinoic acid; bioavailability | HU, OLIVER YOA-PU (TW) | 2003-09-04 | — | — | US | disclosed |
| US-20030166583-A1 | Such as epicatechin coadministered with retinoic acid; bioavailability | HU, OLIVER YOA-PU (TW) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (24 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149346-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | PRDX4, CA4, TOP1 | HSD17B2 1594/4885TAS2R31 2708/4885CYP1A1 321/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | HSD17B2 1898/4885TAS2R31 3770/4885CYP1A1 3564/4885 |
| US-20140155961-A1 | METHODS OF TREATING SKIN | CUTA, LIPA, DLAT | HSD17B2 3077/4885TAS2R31 2843/4885CYP1A1 4290/4885 |
| US-20100272790-A1 | Methods of Treating Skin | CUTA, LIPA, DLAT | HSD17B2 3077/4885TAS2R31 2843/4885CYP1A1 4290/4885 |
| US-20070232495-A1 | Compositions and methods to add value to plant products, increasing the commercial quality, resistance to external factors and polyphenol content thereof | C5, PNN, NQO1 | HSD17B2 4244/4885TAS2R31 2193/4885CYP1A1 444/4885 |
| US-20230241023-A1 | STABILIZATION OF 1,2,4-TRIOXANE COMPOUNDS BY CHLOROGENIC ACIDS | GCK, PCK1, CA4 | HSD17B2 3441/4885TAS2R31 3036/4885CYP1A1 672/4885 |
| US-20250249063-A1 | METHOD FOR TREATING ORAL CANCER | UGGT1, G6PD, UGT1A3 | HSD17B2 2828/4885TAS2R31 124/4885CYP1A1 489/4885 |
| US-20150150770-A1 | METHODS OF TREATING SKIN | CUTA, LIPA, DLAT | HSD17B2 3077/4885TAS2R31 2843/4885CYP1A1 4290/4885 |
| US-20030166583-A1 | Such as epicatechin coadministered with retinoic acid; bioavailability | CYP51A1, CYP2E1, CYP7A1 | HSD17B2 61/4885TAS2R31 1222/4885CYP1A1 7/4885 |
| US-20240350476-A1 | Smoking Cessation Aid | NNMT, BHMT2, MAT2B | HSD17B2 2214/4885TAS2R31 2585/4885CYP1A1 3016/4885 |
| US-20160184298-A1 | INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) | UGT2B7, UGT2B17, UGT1A10 | HSD17B2 91/4885TAS2R31 837/4885CYP1A1 28/4885 |
| US-20240293492-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | UGGT1, G6PD, UGDH | HSD17B2 2981/4885TAS2R31 382/4885CYP1A1 950/4885 |
| US-20260115294-A1 | DERIVATIVES OF 5-HYDROXYLATED POLYMETHOXYFLAVONES WITH ENHANCED BIOAVAILABILITY FOR ORAL DELIVERY AND COMPOSITIONS THEREOF | PLIN3, PNLIP, FABP2 | HSD17B2 2027/4885TAS2R31 965/4885CYP1A1 119/4885 |
| US-20130023552-A1 | Small molecules with antimalarial activity | MAVS, RHOT2, AURKAIP1 | HSD17B2 3851/4885TAS2R31 4833/4885CYP1A1 1471/4885 |
| US-20060216251-A1 | Topical formulations and methods of use | CPT1B, SLC25A20, CPT1A | HSD17B2 3166/4885TAS2R31 2861/4885CYP1A1 2684/4885 |
| US-12569530-B2 | Tannin-based antiproliferative pharmaceutical | SLC2A3, SLC2A1, SLC2A8 | HSD17B2 1467/4885TAS2R31 305/4885CYP1A1 469/4885 |
| US-20240216296-A1 | POLYPHENOL COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY | FABP2, HDLBP, FABP1 | HSD17B2 4325/4885TAS2R31 2916/4885CYP1A1 1133/4885 |
| US-20230210931-A1 | TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL | UGGT1, G6PD, UGDH | HSD17B2 2981/4885TAS2R31 382/4885CYP1A1 950/4885 |
| US-20100087469-A1 | Natural product derivatives with antimalarial activity | CYP51A1, LSS, PMAIP1 | HSD17B2 2348/4885TAS2R31 4722/4885CYP1A1 445/4885 |
| US-12318422-B2 | Tannin-based antiproliferative pharmaceutical | UGGT1, G6PD, UGDH | HSD17B2 2981/4885TAS2R31 382/4885CYP1A1 950/4885 |
| US-20060040875-A1 | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) | UGT2B7, UGT1A3, UGT2B17 | HSD17B2 64/4885TAS2R31 1177/4885CYP1A1 36/4885 |
| US-20090074708-A1 | Inhibitors and Enhancers of Uridine Diphosphate-Glucuronosyltransferase 2B (UGT2B) | UGT2B7, UGT2B17, UGT1A10 | HSD17B2 91/4885TAS2R31 837/4885CYP1A1 28/4885 |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | HTR2C, GRIN2C, HTR5A | HSD17B2 2273/4885TAS2R31 899/4885CYP1A1 416/4885 |
| US-20210292296-A1 | 1,2,4-Trioxane compounds and compositions comprising the same for use in the treatment of COVID-19 | ACE2, ACE, DDX18 | HSD17B2 334/4885TAS2R31 2346/4885CYP1A1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.